European CDMO Capacity 2026: Biologics, Fill-Finish, Small Molecule

For clinical-to-commercial biologics, the first tier of European operators the directory surfaces sits in Switzerland and Germany. Switzerland hosts Lonza (Visp) for integrated biologics and ADC manufacturing, Celonic (Basel) for biologics process development, CARBOGEN AMCIS (Bubendorf) for small molecule and ADC manufacturing, and Siegfried (Zofingen) for API and small-molecule CDMO. Germany adds Rentschler Biopharma (Laupheim) for biologics CDMO at clinical-to-commercial scale, Vetter Pharma (Ravensburg) for sterile fill-finish, IDT Biologika (Dessau-Rosslau) for viral vector and vaccine manufacturing, ProBioGen (Berlin) for cell-line development and high-yield CHO, and FyoniBio (Heidelberg) for biosimilar and biologics development services. For most sponsors running a European CDMO search, these ten names form the shortlist.

Denmark hosts two biologics CDMO operators worth including in a pan-European shortlist. FUJIFILM Diosynth Biotechnologies Denmark (Hillerod) provides mammalian biologics manufacturing across clinical and commercial scales, operating at the Hillerod site FUJIFILM acquired from Biogen in 2019. AGC Biologics Denmark (Soborg) provides biologics process development and manufacturing as part of AGC’s European footprint (Heidelberg + Soborg). Together they give Northern Europe two biologics CDMO options outside the Swiss-German axis, useful for sponsors seeking redundancy or a Nordic-based manufacturing partner.

The Baltics host a visible CDMO layer that sponsors sometimes overlook. Lithuania holds two biologics operators (Northway Biotech and Biotechpharma, both listed under the Northway group in the directory, both in Vilnius). Latvia holds three small-molecule and chemistry CDMOs — AS Grindeks, Olpha (listed in the directory as Olainfarm, rebranded Olpha in 2023), and PharmIdea — all in or near Olaine or Riga. Estonia adds Icosagen Group (biologics research, Tartu) and TBD Pharmatech (drug-development services, Tartu). None operate at Lonza-scale, but together the Baltics form an EU-internal nearshore CDMO option with English-fluent teams, EU regulatory alignment, and GDP-certified logistics through Vilnius.

Poland holds a smaller CDMO count but contributes specific modalities. Mabion S.A. (Łódź) runs antibody biosimilar and originator CDMO services. Rezon Bio (Gdansk / Warsaw) provides biologics and process development services. Around these operators, Poland’s wider biotech belt (Selvita for development services in Kraków, Pure Biologics and Genomtec in Wroclaw) gives sponsors access to a discovery-plus-development layer that pairs well with German or Baltic manufacturing capacity downstream.

Finland’s CDMO layer is specialised. 3PBIOVIAN in Turku provides biologics manufacturing. FinVector in Kuopio operates viral vector manufacturing at late clinical and commercial scale, particularly for AAV and adenoviral programmes — one of the few European operators with that scope disclosed publicly. Nanoform Finland in Helsinki operates a nanoform particle-engineering service used in formulation and bioavailability enhancement. Paras Biopharmaceuticals Finland and Pharmatory in Oulu provide chemistry and CDMO services. Finland is not a generalist biologics CDMO cluster — but for specific modalities (viral vector, particle engineering, specialised chemistry), it surfaces operators that are not common elsewhere in the directory.

Sweden holds a smaller CDMO footprint in the directory (Recipharm in Stockholm, Bioglan in Malmo). Recipharm operates broader CDMO services across sterile fill-finish, small molecule, and biologics. Bioglan provides topical and dermal CDMO services. Around these CDMOs, Sweden’s dense academic biotech layer (Karolinska-linked operators in Solna, Lund’s therapeutics cluster, Uppsala’s bioprocess-tools base) often pairs naturally with CDMOs located elsewhere in Europe rather than inside Sweden itself.

Three filters narrow the shortlist quickly. First, modality: biologics at scale (Lonza, Rentschler, FUJIFILM Denmark, AGC Biologics) vs. sterile fill-finish (Vetter, Vetter-adjacent specialists) vs. viral vector (FinVector, IDT Biologika) vs. particle engineering (Nanoform) vs. peptides or oligo (Bachem — outside the CDMO category strictly, but adjacent) vs. antibodies and biosimilars (Mabion, FyoniBio). Second, scale: commercial-launch depth (Lonza, Rentschler, FUJIFILM, AGC) vs. clinical-scale optionality (Baltic and Finnish specialists, ProBioGen, Celonic). Third, geography and regulatory fit: EU-internal for simplicity (Baltics, Germany, Poland, Finland), Switzerland with EU-aligned logistics, or Denmark for a Nordic-based operator. The Memel Biotech directory entry for each operator links to the current public disclosures so sponsors can verify capability before outreach.